28 November 2020 - Patients living with one of Australia’s most common forms of leukaemia are set to benefit from expanded access to a breakthrough medicine through the Pharmaceutical Benefits Scheme.
From 1 December, access to Venclexta (venetoclax) will be extended in combination with obinutuzumab for the first-line treatment of patients with chronic lymphocytic leukaemia who have co-existing conditions and are unsuitable for fludarabine-based chemo-immunotherapy.